What is HC Wainwright's Estimate for AMLX FY2026 Earnings?

Key Points

• HC Wainwright forecasts Amylyx will lose $1.51 per share in FY2026, slightly more than the consensus estimate of a $1.49 loss, and rates the stock “Strong Buy.”
• The analyst projects losses narrowing to $1.42 per share in FY2027 and $0.99 in FY2028, followed by earnings of $3.06 per share in FY2029 and $6.13 in FY2030.
• Amylyx’s reported quarterly loss of $0.38 per share matched consensus. Analyst opinion is mixed overall, though MarketBeat reports an average “Buy” rating and a $44.14 average price target.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Equities researchers at HC Wainwright issued their FY2026 EPS estimates for Amylyx Pharmaceuticals in a research report issued on Thursday, November 5th. HC Wainwright analyst A. Ghosh forecasts that the company will earn ($1.51) per share for the year. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals' Q4 2026 earnings at ($0.36) EPS, FY2027 earnings at ($1.42) EPS, FY2028 earnings at ($0.99) EPS, FY2029 earnings at $3.06 EPS and FY2030 earnings at $6.13 EPS.

AMLX has been the topic of a number of other reports. Weiss Ratings restated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a report on Tuesday, November 3rd. Wolfe Research upgraded Amylyx Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 17th. Citigroup lifted their price target on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a "buy" rating in a research note on Thursday, October 15th. Robert W. Baird boosted their price objective on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a report on Wednesday, August 19th. Finally, Guggenheim upped their price objective on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a "buy" rating in a research note on Thursday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $44.14.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $29.50 on Monday. Amylyx Pharmaceuticals has a one year low of $10.83 and a one year high of $41.14. The stock has a fifty day moving average of $30.00 and a 200-day moving average of $20.41. The company has a market capitalization of $3.29 billion, a PE ratio of -20.49 and a beta of -0.09.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at about $158,534,000. Jupiter Topco LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth $94,014,000. Siren L.L.C. purchased a new stake in shares of Amylyx Pharmaceuticals during the 1st quarter worth about $17,097,000. Alyeska Investment Group L.P. bought a new stake in Amylyx Pharmaceuticals in the second quarter worth approximately $18,912,000. Finally, Almitas Capital LLC bought a new stake in Amylyx Pharmaceuticals in the second quarter worth $17,509,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Gina Mazzariello sold 9,536 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.46, for a total value of $309,538.56. Following the completion of the sale, the insider owned 190,838 shares in the company, valued at $6,194,601.48. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George M. Milne, Jr. sold 30,000 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the sale, the director owned 782,881 shares of the company's stock, valued at $21,685,803.70. The trade was a 3.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 60,374 shares of company stock valued at $1,815,257. 10.90% of the stock is currently owned by company insiders.

Trending Headlines about Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $55 price target, while forecasting quarterly losses to narrow from $0.38 per share in Q1 2027 to $0.32 in Q4 2027. The rating and target may support investor optimism. Analyst estimates and rating
• Neutral Sentiment: Amylyx reported a Q3 2026 loss of $0.38 per share, matching the consensus estimate. The in-line result was not a positive earnings surprise. Third-quarter financial results
• Neutral Sentiment: The company’s Q3 2026 earnings-call transcript was published, but the provided coverage does not detail additional announcements or outlook changes from the call. Q3 2026 earnings-call transcript

Amylyx Pharmaceuticals Company Profile

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.